NCT03325010 - Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome | Biotech Hunter

Enrollment

127

Participants

Timeline

Start Date

October 5, 2017

Primary Completion Date

November 1, 2018

Study Completion Date

November 16, 2018

Conditions

Tourette Syndrome

Interventions

DRUG

Valbenazine

vesicular monoamine transporter 2 (VMAT2) inhibitor

DRUG

Placebo oral capsule

non-active dosage form

Trial Locations (35)

10036

Neurocrine Clinical Site, New York

10467

Neurocrine Clinical Site, The Bronx

27705

Neurocrine Clinical Site, Durham

32763

Neurocrine Clinical Site, Orange City

32801

Neurocrine Clinical Site, Orlando

32803

Neurocrine Clinical Site, Orlando

33012

Neurocrine Clinical Site, Hialeah

33013

Neurocrine Clinical Site, Hialeah

33018

Neurocrine Clinical Site, Hialeah

33470

Neurocrine Clinical Site, Loxahatchee Groves

33609

Neurocrine Clinical Site, Tampa

38119

Neurocrine Clinical Site, Memphis

52242

Neurocrine Clinical Site, Iowa City

60563

Neurocrine Clinical Site, Naperville

60634

Neurocrine Clinical Site, Chicago

60637

Neurocrine Clinical Site, Chicago

66206

Neurocrine Clinical Site, Leawood

68526

Neurocrine Clinical Site, Lincoln

72758

Neurocrine Clinical Site, Rogers

75062

Neurocrine Clinical Site, Irving

75243

Neurocrine Clinical Site, Dallas

77058

Neurocrine Clinical Site, Houston

85351

Neurocrine Clinical Site, Sun City

91321

Neurocrine Clinical Site, Santa Clarita

92108

Neurocrine Clinical Site, San Diego

92805

Neurocrine Clinical Site, Anaheim

98105

Neurocrine Clinical Site, Seattle

98201

Neurocrine Clinical Site, Everett

99204

Neurocrine Clinical Site, Spokane

06519

Neurocrine Clinical Site, New Haven

02114

Neurocrine Clinical Site, Boston

03060

Neurocrine Clinical Site, Nashua

07856

Neurocrine Clinical Site, Mount Arlington

08043

Neurocrine Clinical Site, Voorhees Township

00926

Neurocrine Clinical Site, San Juan